Zinzani PL, Santoro A, Gritti G, et al. - In the expansion cohort of the open-label, phase I/II CheckMate 436 study of individuals with verified relapsed/refractory (R/R) primary mediastinal B-cell lymphoma (PMBL, rare but aggressive non-Hodgkin lymphoma with poor outcomes in individuals with R/R disease) who were formerly treated with either autologous hematopoietic cell transplantation or two or more earlier chemotherapy regimens if inappropriate for autologous hematopoietic cell transplantation, experts assessed whether the combination of nivolumab and brentuximab vedotin (BV) was safe and synergistically efficient in individuals with R/R PMBL. With high antitumor activity and a flexible safety profile, the combination of nivolumab plus BV signifies an encouraging option in persons with R/R PMBL.